BackXeris Biopharma Holdings Overview
Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Target Price

Analysts' average 12-month price target for Xeris Biopharma Holdings is $14.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.49

Average Target Price

$14.0086.9% upside

2 analysts in the last 4 months

High: $16 | Low: $12

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-10Leerink PartnersRoanna Ruiz$16113.6% upsideOpen
2026-08-20Barclays$1260.2% upsideOpen
2025-12-08Barclays$920.2% upsideOpen
2025-10-29OppenheimerLeland Gershell$18140.3% upsideOpen
2025-03-07Piper Sandler$446.6% downsideOpen
2024-11-11H.C. WainwrightOren Livnat$6.611.9% downsideOpen
2024-10-23OppenheimerLeland Gershell$533.2% downsideOpen
2024-05-10Piper SandlerDavid Amsellem$359.9% downsideOpen
2022-04-28Craig-Hallum$6.513.2% downsideOpen

Xeris Biopharma Holdings (XERS) FAQ

As of the most recent data, XERS shows a target price of $14. Scroll down for historical charts and peer comparison views.

If Xeris Biopharma Holdings moved to the average analyst target of $14, shares would be roughly 86.9% higher than $7.49. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Xeris Biopharma Holdings's earnings trajectory.

Besides this target price page, Stockcircle has Xeris Biopharma Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $14) with ownership activity and broader fundamentals.

Xeris Biopharma Holdings's target price is $14; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.